Savara

NASDAQ: SVRA

$5.02USD

-0.14 (-271.32%)At close: Apr 29, 11:13 UTC

Open

$5.06

Prev. Close

$5.07

High

$5.07

Low

$5.02

Key Stats

Market Cap

$1.02B

Dividend Yield

–

P/E Ratio

-8.6

EPS

-0.47

Revenue

Avg. Volume

1.3M

TL;DR

emptyResult

Recently from Cashu

FDA Extends Priority Review for Savara’s Molgramostim by Three Months Amid Amendments

Savara Pharmaceuticals, a company focused on developing therapies for rare respiratory diseases, announces that the FDA has extended the Priority Review of its Biologics License Application (BLA) for…

Cashu Markets·20h ago

Savara: Pioneering Innovative Respiratory Therapies Amid Growing Healthcare Demand

Savara's Position in the Evolving Landscape of Respiratory Therapeutics Savara, a company specializing in the development of novel therapies for respiratory diseases, is well-positioned to capitalize…

Cashu Markets·5 months ago

Savara Advances Respiratory Therapies with Promising Progress in Pulmonary Treatments

Savara Advances in Respiratory Therapeutics Amidst Market Optimism Savara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases, continues to…

Cashu Markets·5 months ago

Savara Faces Class Action Lawsuit Over Alleged Securities Fraud Regarding MOLBREEVI Approval

Savara Faces Class Action Lawsuit Over Alleged Securities Fraud Savara Inc., a biopharmaceutical company focused on developing treatments for rare respiratory diseases, is embroiled in a class action…

Cashu Markets·6 months ago